Obesity: Evolving Perceptions from Providers and Payers on Treatments for Chronic Weight Management

IPD Analytics has released a new report: “Obesity: Evolving Perceptions from Providers and Payers on Treatments for Chronic Weight Management.”

Drawing on quantitative surveys completed by PCPs, endocrinologists, and payers in July 2026, this report captures the latest prescribing preferences and coverage trends for approved anti-obesity medications (AOMs), including anticipated perceptions of Novo Nordisk's CagriSema, Eli Lilly's retatrutide, and Boehringer Ingelheim's survodutide.

Key findings include tirzepatide products currently holding a slight market advantage over semaglutide, oral AOMs accounting for 11-12% of the market, and AOM coverage among commercially insured groups remaining relatively flat compared to prior surveys. As new competitors enter the CWM space, payers anticipate downward price pressure and evolving management strategies, while providers continue to prioritize efficacy and tolerability in treatment decisions.

IPD’s Primary Market Insights provide a window into the dynamic market pulse of rapidly evolving competitive landscapes and disease areas. Subscribers can access additional up-to-date information through the IPD Analytics platform.

Content on this site is proprietary to IPD Analytics. This sample is not for distribution. By receiving it, you agree to refrain from any unauthorized use, including uploading or inputting it into AI tools or large language models (LLMs) for training or any other purpose. This is strictly prohibited.